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Unique presentations and chronic complications in adult cystic
fibrosis: do they teach us anything about CFTR?
Michael P Boyle
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Abstract
The increase in numbers of adults with cystic fibrosis (CF) has allowed us to identify
previously unrecognized chronic complications of CF, as well as appreciate unique
presentations of cystic fibrosis-related diseases. Do these chronic complications and unique
presentations provide us with new insight into cystic fibrosis transmembrane conductance
regulator (CFTR) function? Current data suggest that the ‘chronic complications’ reveal
mainly the effect of a long-term absence of previously recognized CFTR functions. In
contrast, the ‘unique presentations’ provide new insight into the role of CFTR in different
tissues.
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Introduction
One of the most striking trends in cystic fibrosis (CF) over
the past few decades has been the marked increase in
expected life span, with median survival improving from
less than 10 years in the 1960s to more than 30 years
now. Currently more than one-third of all individuals with
CF are over the age of 18 [1], and trends suggest that in
the next decade adults will account for nearly half of the
CF population. It is accepted that new insights into the
basic pathophysiology of CF might allow continued
increases in survival, but is the converse also true? Will
increased survival allow greater insight into the basic
pathophysiology of CF? This question can be asked
because with increased length of survival has come the
recognition of previously underappreciated CF-related
complications including an increased risk of gastrointesti-
nal and perhaps pancreatic malignancy, osteoporosis, and
diabetes. Furthermore, greater attention to ‘adult’ CF has
also led us to identify, with increased frequency, atypical
presentations of dysfunction of cystic fibrosis transmem-
brane conductance regulator (CFTR): chronic pancreatitis,
congenital bilateral absence of the vas deferens (CBAVD),
chronic sinusitis, and allergic bronchopulmonary
aspergillosis. Do these unique presentations and chronic
complications of adult CF teach us anything about the
function of CFTR?
Complications in adult CF
When deciding whether the complications of adult CF
provide us with insight into CFTR function, the key questionRespiratory Research    Vol 1 No 3 Boyle
to ask is: do these complications suggest previously
unrecognized functions for CFTR, or are they due to the
long-term absence of already recognized CFTR functions?
A prime example of an area in which this question should
be asked is the role of CFTR dysfunction in increasing the
risk for malignancy. A study in 1995 by Neglia et al [2] on
the risk of cancer in patients with CF revealed that
although the overall risk for cancer is similar to that of the
general population, there is an increased risk for digestive
tract cancers. In particular, there is an increased risk for
ileal and colonic adenocarcinoma. Similar results were
found in an earlier study by Sheldon et al [3]. Other
reports have suggested an association between CF and
pancreatic adenocarcinoma [3,4]. The key question is: are
these neoplasms related to previously unrecognized func-
tions of CFTR, or are they secondary to chronic inflamma-
tion, infection, or malnutrition, which might predispose to
malignancy?
At present there is no evidence that CFTR mutations are
directly responsible for oncogenicity. To start with, when
the data from Neglia et al [2] are examined more closely,
only one of the 24 cases of malignancy identified occurred
in a patient under 20 years of age. A similar trend is seen
when reviewing reported cases of CF and pancreatic
malignancy: none has occurred before the age of 25
[4–6]. If CFTR mutations were directly oncogenic, it is
likely that malignancies would be seen more frequently
early in life. In 1997, Padua et al attempted to look directly
at the relationship between the DF508 mutation and
malignancy by screening more than 1700 patients with
one of six different common tumors including colon,
breast, lymphoma, and leukemia, for the DF508 mutation.
Not only was there not an increased frequency of DF508
presence in any of the malignancy groups compared with
a control group, there was actually a lower than expected
frequency in patients with colonic adenocarcinoma [7].
Until evidence to the contrary is found, it must be
assumed that the increased risk of certain malignancies
seen in CF is secondary not to previously unidentified
roles of CFTR but to the long-term absence of already rec-
ognized CFTR functions. In gastrointestinal malignancy
several mechanisms have been suggested, including a
change in the functional environment of the small bowel
owing to abnormal bile acid metabolism [3], chronic steat-
orrhea [3], and selenium and vitamin E deficiency [8].
Other common adult-onset CF complications include dia-
betes and osteoporosis. Again, it is unlikely that these
complications suggest previously unrecognized roles for
CFTR. CF-related diabetes develops on average at around
20 years of age in individuals with long-standing pancre-
atic exocrine insufficiency. It is known that CFTR has a key
role in the ductal epithelium of the pancreas, and its dys-
function is thought to result in protein hyperconcentration,
precipitation and obstruction within pancreatic ducts. The
subsequent parenchymal damage is likely to contribute to
the development of diabetes and has been documented in
autopsy studies of CF-related diabetes: pancreatic ductal
blockage and dilatation, fatty and fibrotic replacement of
tissue, severe loss of b cells, and significant amyloid depo-
sition [9,10]. Despite some evidence for alterations in
insulin secretion independent of b cell destruction, there is
currently insufficient evidence to propose new pancreatic
roles for CFTR. Similarly, osteopenia/osteoporosis, which
is present in 65% or more of adults with CF [11], is
unlikely to provide great insight into CFTR. CFTR expres-
sion has not been documented in osteoblasts or osteo-
clasts. Studies suggest that bone disease in CF is
probably multifactorial, owing to a combination of malnutri-
tion (vitamin D and calcium) [12], circulating cytokines
[13], inadequate androgens and estrogens [14], and
exogenous use of glucocorticoids.
Unique presentations
In contrast with chronic complications, however, unique
presentations of CFTR-related diseases in adults have
provided significant insight into CFTR function. This has
occurred in particular in isolated presentations of
CFTR-related diseases such as CBAVD, chronic pancre-
atitis, and chronic sinusitis with nasal polyposis. All of
these have helped to provide an understanding of the hier-
archy of tissue sensitivity to CFTR dysfunction.
It is clear from these atypical presentations of CFTR dys-
function that it is the vas deferens, pancreas, and sinuses
that are the tissues most sensitive to decreases in CFTR
function. The sensitivity of the vas deferens was first rec-
ognized in adult men with CBAVD and otherwise non-CF
phenotypes. A recent study of more than 800 men with
isolated CBAVD found that 71% had two CFTR mutations
[15]. Almost universally they had at least one Class IV or
Class V CFTR mutation, which results in levels of CFTR
function estimated to be about 10% of normal [16].
Women with similar mutations have been reported to have
thick cervical mucus and hypofertility, suggesting a possi-
ble female equivalent to CBAVD that affects the para-
mesonephric ducts [17]. Because only a small portion of
men with CBAVD have evidence of lung, sinus or pancre-
atic pathology, we must conclude that in general it is the
mesonephric and paramesonephric ducts that are among
the most sensitive tissues to CFTR dysfunction.
The more recently recognized entity of CFTR-related pan-
creatitis suggests that the pancreas is also particularly
sensitive to CFTR dysfunction. A study by Cohn et al [18]
screened a cohort of 27 patients with chronic idiopathic
pancreatitis for 17 common CF mutations and the 5T
allele in intron 8 of the gene for CFTR. Despite this limited
screening, 37% of them had at least one CFTR mutation,
and 11% had two identifiable CFTR mutations; 19% of
the patients had the 5T allele in intron 8 of the gene forc
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CFTR, a mutation that permits the formation of a small
amount of normal CFTR but causes the vast majority of
CFTR transcripts to lack exon 9 and be dysfunctional.
Only one of the patients had CBAVD and none had CF
sinopulmonary disease. This suggests that, like the vas
deferens, the pancreas is among the most sensitive
tissues to CFTR dysfunction. The manifestation of CFTR
dysfunction in the pancreas is determined by the degree
of decrease in CFTR levels, with a decrease to 10% of
normal leading to an increased risk for pancreatitis, and a
decrease to levels less than 1% leading invariably to
exocrine pancreatic insufficiency. Further research is
needed to determine whether the CFTR deficiency leads
directly to pancreatitis or whether it increases the risk of
pancreatitis only after exposure to stressors [19].
The third group of patients that give us insight into tissue
sensitivity to decreases in CFTR function are patients with
chronic sinusitis and polyposis. The evidence is mounting
that a moderate decrease in CFTR function can lead to
isolated sinus disease. A recent study by Wang et al [20]
found an increased frequency of CF mutations in patients
with chronic sinusitis and otherwise non-CF phenotypes.
Friedman et al [21] noted an association of the 5T allele
with atypical sinopulmonary disease. In retrospect, some
of the men initially studied and identified as having
CFTR-related CBAVD were noted later to exhibit symp-
toms of sinus disease [22].
Conclusion
So, although adult CF complications such as colonic
malignancy, diabetes, and osteoporosis have not provided
significant new insights into CFTR function, the unique
presentations of CF-related diseases in adults have done
so. CBAVD, pancreatitis and sinus disease have given us
a better understanding of the hierarchy of tissue sensitivity
to CFTR dysfunction. In future the study of these disease
presentations, as well as other unusual presentations of
CFTR dysfunction such as allergic bronchopulmonary
aspergillosis [23] and idiopathic disseminated brochiecta-
sis [24], might lead to the identification of previously
unidentified roles for CFTR.
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